MDS 2022 | Subcutaneous levodopa/carbidopa infusion for Parkinson’s disease

Continuous dopaminergic therapies allow the control of motor and non-motor fluctuations characterized by the progression of Parkinson’s disease. Eric Freire-Alvarez, MD, University General Hospital of Elche, Elche, Spain, discusses the future of continuous subcutaneous levodopa/carbidopa infusion in the therapeutic armamentarium. Subcutaneous delivery is more convenient for patients than intestinal levodopa/carbidopa gel infusion or deep brain stimulation. Therefore, its availability would be a positive addition to Parkinson’s disease treatment options. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.